Com.PI.it DX®
Lung
Com.Pl.it DX® Lung focuses on patients with Non-Small-Cell Lung Carcinoma (NSCLC) and it is designed to achieve maximum...
LEARN MORE
Com.PI.it DX®
Liquid Biopsy
The Com.Pl.it DX® Liquid test is designed for any type of solid tumor and provides a real time monitoring of tumor’s molecular...
LEARN MORE
Com.PI.it DX®
Colon
Com.Pl.it DX® Colon focuses on patients with metastatic colorectal cancer and is designed to achieve maximum sensitivity...
LEARN MORE
Com.PI.it DX®
for Lung & Colon Cancer
The Com.Pl.it DX® multigene assay provides important insight to the tumor’s biology either by analyzing the tissue removed during surgery or biopsy or by analyzing cell –free circulating DNA on the patient’s blood.
Understanding the tumor biology can lead to identifying mutations that cause the cancer to grow, also known as “driver mutations”.
These mutations can provide information that lead to effective targeted treatments to patients and physicians.
5 cases where Individualized Treatment is needed
Initial treatment plan has been completed and more treatment options are needed.
Tumors without an established “gold standard” treatment.
Tumors that are aggressive and do not respond to standard treatment.
Rare tumors.
Tumor types with different targeted treatment options available such as lung cancer.
